Description

Tirzepatide is a synthetic dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This novel class of therapeutic agents, known as twincretins, has been developed to enhance the physiological regulation of blood glucose and body weight by acting on two complementary incretin pathways.

Research involving tirzepatide has demonstrated significant improvements in insulin sensitivity, glycemic control, and appetite regulation, making it highly relevant in studies addressing metabolic disorders such as type 2 diabetes and obesity. It enhances glucose-dependent insulin secretion, delays gastric emptying, and reduces food intake. Additionally, tirzepatide has been studied for its ability to promote weight loss by modulating energy balance and satiety signals.

The 5 mg dosage form is commonly used in clinical and preclinical studies to evaluate its metabolic, hormonal, and cardiovascular effects over time. Ongoing research continues to explore its potential advantages over single-pathway GLP-1 receptor agonists.